Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147–e159.

Article  PubMed  CAS  Google Scholar 

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol. 2019;6:e89–e99.

Article  PubMed  Google Scholar 

Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.

Article  PubMed  Google Scholar 

Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132–e143.

Article  PubMed  PubMed Central  Google Scholar 

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized Phase III BMT CTN Trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022;40:356–68.

Article  PubMed  CAS  Google Scholar 

Jurdi NE, Hoover A, O’Leary D, Cao Q, Gupta A, Ebens C, et al. Phase II Study of Myeloablative 7-8/8-Matched allotransplantation with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil. Transpl Cell Ther. 2023;29:576-e1.

Marco-Ayala J, Sanz J, Gomez-Segui I, Balaguer-Rosello A, Montoro J, Guerreiro M, et al. Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation. Transpl Cell Ther. 2023;29:313 e311–313.e310.

Article  Google Scholar 

Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, et al. Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation. Transpl Cell Ther. 2022;28:695 e691–695.e610.

Google Scholar 

Lv X, Qi J, Zhou M, Shi B, Cai C, Tang Y, et al. Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis. Crit Rev Oncol Hematol. 2020;150:102944.

Article  PubMed  Google Scholar 

Brissot E, Lapobin M, Labussiere H. Post-transplantation cyclophosphamide versus antithymocyte globulin after Ric regimen Allo-Hct: first analysis of a prospective randomized multicenter trial in recipients of 10/10 matched donors. Bone Marrow Transpl. 2021;56:12–13.

Google Scholar 

Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, et al. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica. 2022;107:857–67.

Article  PubMed  CAS  Google Scholar 

Salas MQ, Charry P, Pedraza A, Martinez-Cibrian N, Solano MT, Domenech A, et al. PTCY and Tacrolimus for GVHD prevention for older adults undergoing HLA-matched sibling and unrelated donor AlloHCT. Transplant Cell Ther. 2022;28:489 e481–489 e489.

Article  Google Scholar 

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22:4–10.

Article  Google Scholar 

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

Article  PubMed  CAS  Google Scholar 

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

Article  Google Scholar 

Penack O, Abouqateb M, Peczynski C, Boreland W, Kroger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?. Leukemia. 2024;38:1156–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Westphal S, Brinkmann H, Kalupa M, Wilke A, Seitz-Merwald I, Penack O. Anti-tumor effects of anti-T-cell globulin. Exp Hematol. 2014;42:875–82.

Article  PubMed  CAS  Google Scholar 

Penack O, Abouqateb M, Peczynski C, Boreland W, Gulbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45.

Article  PubMed  PubMed Central  Google Scholar 

Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.

Article  PubMed  CAS  Google Scholar 

Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JL, et al. Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:1915–22.

Article  CAS  Google Scholar 

Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357–73.

Article  PubMed  PubMed Central  Google Scholar 

McAdams MJ, Hyder M, Dimitrova D, Sadler JL, McKeown C, Steinberg SM, et al. Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood. 2021;138:101.

Article  Google Scholar 

Chen TT, Lin CC, Lo WJ, Hsieh CY, Lien MY, Lin CH, et al. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies. Int J Hematol. 2022;115:525–33.

Article  PubMed  CAS  Google Scholar 

Gao WH, Zhu JY, Wang LN, Wan M, Wang L, Devillier R, et al. Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis. Front Med. 2023;10:1140217.

Article  Google Scholar 

Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. Br J Haematol. 2023;200:210–21.

Article  PubMed  CAS  Google Scholar 

Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, et al. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer. 2024;130:3123–36.

Article  PubMed  CAS  Google Scholar 

Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3:250–9.

Article  PubMed  PubMed Central  Google Scholar 

Massey RJ, Diep PP, Ruud E, Burman MM, Kvaslerud AB, Brinch L, et al. Left ventricular systolic function in long-term survivors of allogeneic hematopoietic stem cell transplantation. JACC CardioOncol. 2020;2:460–71.

Article  PubMed  PubMed Central  Google Scholar